Study backs gene therapy for heart failure:
This article was originally published in Clinica
Collateral Therapeutics' angiogenesis-promoting gene has shown promise as a non-surgical treatment for heart failure, according to results from a placebo-controlled animal study in the March issue of Cardiac and Vascular Regeneration. Intracoronary delivery of the company's human gene fibroblast growth factor-4 (FGF-4) increased heart function and reduced the size of dilated hearts over the three-week study period. The San Diego, California-based company has licensed the gene exclusively from New York University. Collateral is also using the FGF-4 gene to develop a treatment for coronary artery disease.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.